Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Document › Details

Nordic Nanovector ASA. (2/25/21). "Press Release: Nordic Nanovector ASA – Share Capital Increase Registered". Oslo.

Organisation Organisation Nordic Nanovector ASA (OSE: NANOV)
  Group Nordic Nanovector (Group)
Products Product Betalutin®
  Product 2 investment banking
Index term Index term Nordic Nanovector–SEVERAL: investment, 202102 private placement NOK361m ($42.5m) with 15.9m new shares at NOK22.75/share
Person Person Brondberg, Marlene (Nordic Nanovector 201806 VP IR + Corp Communications)
     


Reference is made to the stock exchange announcement on 23 February 2021 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANOV) (the "Company") private placement of new shares (the "Private Placement").

The share capital increase pertaining to the 15,878,122 new shares, each with a nominal value of NOK 0.20, to be issued in the Private Placement (the "New Shares") has been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 25 February 2021, and the Company's share capital has been increased with NOK 3,175,624,40 through the issuance of the New Shares. The New Shares are admitted to listing and made tradable on the Oslo Stock Exchange following this stock exchange announcement.

Following registration of the share capital increase related to the New Shares in the NRBE, the Company has an issued share capital of NOK 19,053,746.80, divided into 95,268,734 shares, each with a par value of NOK 0.20. Each share represents one vote in the Company's general meeting.


For further information, please contact:

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com


About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to the disclose requirements pursuant to Oslo Rule Book II section 4.3.5.5 (4).


   
Record changed: 2021-09-19

Advertisement

Picture Kentro Design Is Key to Your Success Berlin 650x100px

More documents for Nordic Nanovector (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80




» top